A randomized, double‐blind, dose‐controlled study of the use of dexmedetomidine alone for procedural sedation of children and adolescents undergoing MRI scans

• Published in: Pediatric anesthesia Vol. 34; no. 5; pp. 405 - 414
• Main Authors: Khan, Umar, Hammer, Gregory B., Duncan‐Azadi, Cassandra, Suzuki, Yasuyuki, Chiles, Deborah, Chime, Sunring, Chappell, Phillip
• Format: Journal Article
• Language: English
• Published: France Wiley Subscription Services, Inc 01-05-2024
• Subjects: Anesthesia; dexmedetomidine; Magnetic resonance imaging; pediatrics; procedural sedation; dexmedetomidine; magnetic resonance imaging; procedural sedation; pediatrics
• ISSN: 1155-5645; 1460-9592
• DOI: 10.1111/pan.14857

Background
Dexmedetomidine is a selective α2‐adrenergic agonist originally approved for sedation of adults in the intensive care unit and subsequently approved for procedural sedation in adults undergoing medical procedures. Dexmedetomidine is widely used off‐label for procedural sedation in children.
Aims
To evaluate efficacy and safety of monotherapy dexmedetomidine for magnetic resonance imaging procedural sedation of children ≥1month–<17years across three ascending doses.
Methods
Randomized, double‐blind, dose‐ranging study of procedural sedation recruited patients at USA and Japanese sites from February 2020 to November 2021. Patients were stratified into Cohort A (≥1month–<2years) or Cohort B (≥2–<17years). Cohort A loading doses/maintenance infusions: 0.5 mcg/kg/0.5 mcg/kg/h, 1.0 mcg/kg/1.0 mcg/kg/h, and 1.5 mcg/kg/1.5 mcg/kg/h. Cohort B loading doses/maintenance infusions: 0.5 mcg/kg/0.5 mcg/kg/h, 1.2 mcg/kg/1.0 mcg/kg/h, and 2.0 mcg/kg/1.5 mcg/kg/h. Primary endpoint was percentage of overall patients completing MRI without rescue propofol at the high versus low dose. Key secondary endpoint was percentage in each age cohort who did not require propofol at the high versus low dose.
Results
One hundred twenty‐two patients received high‐ (n = 38), middle‐ (n = 42), or low‐dose (n = 42) dexmedetomidine. A greater percentage completed MRI without propofol rescue, while receiving high‐ versus low‐dose dexmedetomidine (24/38 [63.2%] vs. 6/42 [14.3%]) (odds ratio: 10.29, 95% confidence interval: 3.47–30.50, p < .001). Similar results were seen in both age cohorts. The most common adverse events were bradypnea, bradycardia, hypertension, and hypotension, and the majority were of mild‐to‐moderate severity.
Conclusions
Dexmedetomidine was well tolerated. The high dose was associated with meaningfully greater efficacy compared with lower doses. Based on these results, the recommended starting dose for procedural sedation in children ≥1month–<2years is loading dose 1.5 mcg/kg/maintenance infusion 1.5 mcg/kg/h; children ≥2–<17years is loading dose 2.0 mcg/kg/maintenance infusion 1.5 mcg/kg/h.